Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.55 |
| ▸ | DDO | Q99489 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528142 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL21226786 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL671495 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL668758 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL29756947 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL1574005 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL435130 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1 | |
| SCHEMBL373592 | 0.78 | DAO (0.64) | DAORIPK1AURKAPARP1 | |
| SCHEMBL30678374 | 0.77 | DAO (0.62) | DAORIPK1 | |
| SCHEMBL27680363 | 0.77 | DAO (0.62) | DAORIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548031-B1 | TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11358711-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3377065-B1 | SPIROCYCLIC PYRIDOTRIAZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-110214142-B | Tetracyclic heterocyclic compounds useful as HIV integrase inhibitors | 默沙东公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3397639-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108473494-A | Fused tricyclic heterocycles compound as hiv integrase inhibitor | 默沙东公司 | 2018-08-31 | — | — | CN | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| EP-2391212-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7279487-B2 | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1467970-B1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1467970-A4 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
| EP-1467970-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062204-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-4103257-A | BLUE TO NEAR ULTRAVIOLET | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | HCLS1, POLR2A, CCNT1 | DAO 2949/4885RIPK1 2862/4885DDO 3809/4885 |
| US-11358711-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | TYMP, IDH1, CCNE1 | DAO 2344/4885RIPK1 1482/4885DDO 3265/4885 |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885RIPK1 3748/4885DDO 2128/4885 |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885RIPK1 3748/4885DDO 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.